In the first half of this year, the R & D investment of these four pharmaceutical enterprises totaled 7.273 billion yuan

[pharmaceutical network industry trends] innovation to pharmaceutical enterprises is like a source to a stream Driven by the policies of "4 + 7" with volume procurement and consistency evaluation, innovation will undoubtedly become the key to continuously promote the layout of pharmaceutical enterprises in the future The R & D investment of enterprises represents the importance of product innovation With the release of 2019h1 financial statements of major pharmaceutical companies, their R & D investment and sales performance are also disclosed The author selected a number of enterprises in the forefront of R & D investment in China for statistics, and found that four enterprises in the first half of 2019 R & D investment performance is very bright, a total of 7.273 billion yuan In the first half of 2019, the R & D investment of four pharmaceutical enterprises, Baiji Shenzhou and Baiji Shenzhou, with R & D investment exceeding 1 billion yuan, was 407 million US dollars (about 2.8 billion yuan), close to the sum of Hengrui and China's biopharmaceuticals If such a money burning pace is maintained in the second half of the year, it is expected that the R & D cost of Baiji Shenzhou in 2019 will reach nearly 5.6 billion yuan, an increase of nearly 20% compared with 2018 At present, Baiji Shenzhou has submitted two drugs for marketing in China, namely tirelizumab injection and zebutinib capsule, all of which have obtained priority review On August 21, zebutini also submitted the listing application in the United States and obtained the priority review qualification granted by FDA The expected listing time is February 27, 2020 China biopharmaceutical industry is the research and development benchmark of the domestic pharmaceutical industry In the first half of the year, the R & D investment reached 1.63 billion yuan, accounting for 13% of the total revenue and all the expenses, mainly because a number of biological similar drugs entered phase III clinical and other small molecules of chemical drugs successively started phase IB and phase II clinical There are 459 products under research (about 40 are in the production reporting stage, PD-1 mAb, adalimumab, recombinant coagulation factor 8, budesonide and other large varieties are expected to be on the market in 19-20 years) On the whole, the company has a large number of potential varieties, orderly product layout, equal emphasis on innovative drugs and generic drugs, and strong R & D strength In fact, Hengrui pharmaceutical has attracted the attention of peers in R & D investment all year round In the 2019 half year report, Hengrui pharmaceutical has invested 1.484 billion yuan in R & D, an increase of 49.13% over the same period of last year The R & D investment accounts for 14.80% of its revenue, which strongly supports its project R & D and innovation development At this stage, Hengrui pharmaceutical is mainly engaged in drug research and development, production and sales, and its main products cover many fields such as anti-tumor drugs, surgical anesthesia drugs, special infusion, contrast agents, cardiovascular drugs, etc It is worth noting that during the reporting period, with the further optimization of product structure of Hengrui medicine, non anti-tumor drugs represented by surgical anesthesia and contrast agents gradually expanded their market in their respective treatment fields At present, Fosun Pharmaceutical's business is mainly divided into three parts: drug manufacturing and R & D, medical services, medical devices and medical diagnosis Among them, pharmaceutical manufacturing and R & D has always been the core of Fosun Pharmaceutical's layout, and in recent years, it has also increased its breakthrough in the medical service sector In the first half of this year, Fosun Pharmaceutical has invested 1.351 billion yuan in R & D, up 13.69% year on year Among them, R & D investment in pharmaceutical business was 1.205 billion yuan, up 13.23% year on year, accounting for 11.1% of pharmaceutical business revenue Compared with other innovative pharmaceutical enterprises horizontally, more than 10% of R & D revenue has been in the echelon of top pharmaceutical enterprises Looking at the annual reports of major pharmaceutical companies in the first half of the year, we can see that, although compared with the industry R & D investment in 2018, the figure has declined But overall, the R & D investment trend of Chinese pharmaceutical companies is still rising Many pharmaceutical companies have chosen to continue to increase investment in research and development, and cluster innovative drug development In the future, the fierce competition in the industry can be imagined Nowadays, the track is obviously overheated How to make differentiated products and use the R & D cost on key points will be the problem that enterprises need to study and solve as soon as possible.